Salsolidine

Salsolidine

SCHEMBL177753

COc1cc2c(cc1OC)C(C)NCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOA P21397 8/20 1.00
TSHR P16473 2/20 1.00
ALDH1A1 P00352 2/20 0.77
HSD17B10 Q99714 2/20 0.77
CYP2D6 P10635 1/20 0.77
KMT2A Q03164 3/20 0.60
MEN1 O00255 2/20 0.60
LMNA P02545 1/20 0.60
DRD2 P14416 2/20 0.59
KDM4E B2RXH2 1/20 0.59
CYP2C9 P11712 1/20 0.59
DRD3 P35462 1/20 0.59
HIF1A Q16665 1/20 0.59
DRD4 P21917 1/20 0.59
PKM P14618 1/20 0.55
GAA P10253 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salsolidine SCHEMBL34461883 1.00 MAOA (1.00) MAOATSHRALDH1A1HSD17B10CYP2D6
Salsolidine SCHEMBL4250569 1.00 MAOA (1.00) MAOATSHRALDH1A1HSD17B10CYP2D6
Salsolidine SCHEMBL1819825 1.00 MAOA (1.00) MAOATSHRALDH1A1HSD17B10CYP2D6
Salsolidine SCHEMBL5242077 0.98 MAOA (1.00) MAOATSHRALDH1A1HSD17B10CYP2D6
Salsolidine SCHEMBL7838872 0.98 MAOA (0.97) MAOATSHRALDH1A1HSD17B10CYP2D6
SCHEMBL7852877 0.90 MAOA (0.81) MAOATSHRALDH1A1HSD17B10CYP2D6
SCHEMBL7848778 0.88 MAOA (0.79) MAOATSHRALDH1A1HSD17B10CYP2D6
SCHEMBL7848489 0.87 MAOA (0.77) MAOATSHRALDH1A1HSD17B10CYP2D6
SCHEMBL7847453 0.87 MAOA (0.77) MAOATSHRALDH1A1HSD17B10CYP2D6
Salsoline SCHEMBL20485120 0.87 MAOA (1.00) MAOATSHRALDH1A1HSD17B10CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569483-B2 Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2026-03-10 US claimed
US-20220211700-A1 Methods for Objective Assessment of Memory, Early Detection of Risk for Alzheimer's Disease, Matching Individuals With Treatments, Monitoring Response to Treatment, and New Methods of Use for Drugs NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-07-07 US claimed
EP-3972975-A1 METHODS FOR OBJECTIVE ASSESSMENT OF MEMORY, EARLY DETECTION OF RISK FOR ALZHEIMER'S DISEASE, MATCHING INDIVIDUALS WITH TREATMENTS, MONITORING RESPONSE TO TREATMENT, AND NEW METHODS OF USE FOR DRUGS Indiana University Research and Technology Corporation (US) 2022-03-30 EP claimed
WO-2020237203-A1 METHODS FOR OBJECTIVE ASSESSMENT OF MEMORY, EARLY DETECTION OF RISK FOR ALZHEIMER'S DISEASE, MATCHING INDIVIDUALS WITH TREATMENTS, MONITORING RESPONSE TO TREATMENT, AND NEW METHODS OF USE FOR DRUGS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2020-11-26 WO claimed
EP-2001877-A1 METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT Bioniqs Limited (GB) 2008-12-17 EP claimed
WO-2007110637-A1 METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT BIONIQS LIMITED (GB) 2007-10-04 WO claimed
US-12569483-B2 Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2026-03-10 US disclosed
EP-4140974-B1 METHODS OF IRON CATALYZED C-H BOND AMINATION VERSITECH LTD (CN) 2025-05-14 EP disclosed
CN-119661514-A Herba corydalis Bungeanae total alkaloid extract for preventing and treating hyperuricemia, and preparation method and application thereof 云南中医药大学 2025-03-21 CN disclosed
US-12098126-B2 Methods of iron catalyzed C-H bond amination VERSITECH LIMITED (CN) 2024-09-24 US disclosed
CN-118146154-A Method for synergistic catalysis of selective oxidative dehydrogenation of tetrahydroisoquinoline 西安石油大学 2024-06-07 CN disclosed
US-20240052418-A1 METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-02-15 US disclosed
CN-115124466-B Synthesis method of tetrahydropapaverine hydrochloride 浙江博崤生物制药有限公司 2024-01-12 CN disclosed
US-4766131-A 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics PENNWALT CORPORATION (US) 1988-08-23 US disclosed
WO-1987007508-A1 METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1987-12-17 WO disclosed
EP-0245960-A2 Process for preparing N-acyltetrahydroisoquinoline Takasago Perfumery Co., Ltd. (JP) 1987-11-19 EP disclosed
EP-0083612-A1 NEW DERIVATIVES OF DIPEPTIDES, METHOD FOR THE PREPARATION THEREOF AND UTILIZATION THEREOF AS DRUGS FLORK, Michel (FR) 1983-07-20 EP disclosed
WO-1983000146-A1 NEW DERIVATIVES OF DIPEPTIDES, METHOD FOR THE PREPARATION THEREOF AND UTILIZATION THEREOF AS DRUGS FLORK, MICHEL 1983-01-20 WO disclosed
US-4365064-A VASODILATORS CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) 1982-12-21 US disclosed
EP-0051190-A2 N-(amino(or hydroxy) phenethyl)-1,2,3,4-tetrahydroisoquinolines, precursors thereof, and methods of preparation PENNWALT CORPORATION (US) 1982-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12098126-B2 Methods of iron catalyzed C-H bond amination FTH1, FECH, HCCS MAOA 45/4885TSHR 1353/4885ALDH1A1 938/4885
US-12569483-B2 Methods for objective assessment of memory, early detection of risk for Alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs PSMB3, THRB, GRIN2B MAOA 1920/4885TSHR 728/4885ALDH1A1 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.